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Summary
Predicting patient outcome in multiple myeloma remains challenging despite the
availability of standard prognostic biomarkers. We investigated outcome for patients
relapsing early from intensive therapy on NCRI Myeloma XI. Relapse within
12 months of autologous stem cell transplant was associated with markedly worse
median progression-free survival 2 (PFS2) of 18 months and overall survival (OS)
of 26 months, compared to median PFS2 of 85 months and OS of 91 months for
later relapsing patients despite equal access to and use of subsequent therapies,
highlighting the urgent need for improved outcome prediction and early interven-
tion strategies for myeloma patients.
Keywords: myeloma, transplantation, prognostic factors.
High-dose melphalan (HDM)-conditioned transplantation in
myeloma has become a standard of care in first remission
justifiable by prolonged progression-free survival (PFS) and
overall survival (OS) compared to chemotherapy alone.1 Fac-
tors known to be associated with longer PFS following autol-
ogous stem cell transplantation (ASCT) include achievement
of a deep response [very good partial response (VGPR)/com-
plete response (CR)]2 and lenalidomide maintenance.3,4 Nev-
ertheless, not all patients benefit from standard treatments
and the ability to predict which patients have disease that
progresses early will improve outcomes. We used data from
the Myeloma XI trial to explore this.
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Patients and methods
Myeloma XI compared immunomodulatory drug (IMiD)-
based triplet induction with thalidomide or lenalidomide
combined with cyclophosphamide and dexamethasone.
Patients who did not achieve at least a VGPR were ran-
domised to proteasome inhibitor-based therapy (bortezomib,
cyclophosphamide and dexamethasone) or no further ther-
apy prior to ASCT. Lenalidomide-based maintenance treat-
ment was also compared to no further therapy following
ASCT. The results of these randomisations have been pub-
lished or are in submission.3,4
The objectives of this analysis were to compare the baseline
characteristics, cytogenetics, treatment, response and outcome
in participants who relapsed within 12 months post HDM–
ASCT to those who did not using the two-sample t-test for
continuous variables and the chi square test for categorical
variables. In addition, the aim was to assess OS and PFS2 based
on time to first relapse post HDM–ASCT. PFS2 was defined as
the time from HDM administration to the time of second doc-
umented disease progression (or the start of the next line anti-
myeloma treatment) or death from any cause, whichever
occurs first. OS was defined as the time from HDM adminis-
tration to death from any cause. Individuals were censored at
the last date they were known to be alive and second progres-
sion-free for PFS2, and alive for OS. The survival function for
PFS2 and OS was estimated using the Kaplan–Meier method.
We compared PFS2 and OS using ratios of incidence rates per
person-month measured in follow-up after first relapse. Inci-
dence rates and rate ratio were assessed using a normal
approximation to the Poisson distribution.
Two groups of patients were defined by the time of their
first relapse. The early relapse (ER) group comprised partici-
pants with progressive disease or a myeloma-related death
within 12 months post HDM administration. Participants
who died within 12 months post HDM administration with-
out evidence of progressive disease were not included in this
group and were censored at the time of death. The non-early
relapse (nER) group comprised of all other participants in
the analysis population who did not have progressive disease
or a myeloma-related death within 12 months post HDM
administration. Cytogenetic risk was analysed in a subset of
patients. Risk was defined as5,6 the presence of any one [high
risk (HiR)] or more than one [ultra-high risk (UHiR)] of
the following lesions: del(17p), gain(1q), t(4,14), t(14;16) or
t(14;20).
Results
Patients and characteristics
Of the 1 349 patients who completed ASCT within the trial,
174 (129%) were in the ER group and 1 175 (871%) were
in the nER group. Within the nER group, 649 participants
(552%) had a progression or death event, and 526
participants (448%) were alive and progression-free at the
time of analysis. Comparison of the baseline characteristics
of participants at initial randomisation demonstrates that
haemoglobin concentration, platelets, plasma cell percentage
in the bone marrow, b2 microglobulin, calcium levels and
International Staging System (ISS) stage significantly differed
between the relapse groups (Table I). All other characteristics
examined did not (Table SI).
More patients were classified as high risk (HiR) or ultra-
high risk (UHiR) in the ER group (Table I). Gain(1q), t
(4,14), del(17p), ‘t(4,14) and/or del(17p)’ and cytogenetic
risk significantly differed between the relapse groups.
The number of patients with UHiR genetics was almost
fourfold higher in the ER group compared to the nER group.
In addition, each of the high-risk lesions del(17p) and t
(4;14) were present in three times more patients with ER
compared to nER. The same was not true for t(14;16) and t
(14;20) although absolute numbers of patients with these
lesions was low.
Comparison of trial treatment received
There were no differences in the randomised trial treatment
during the induction and consolidation phases according to
relapse group; however, the randomised maintenance treat-
ment did differ between groups (Table SII).
Patients in the ER group were less likely to have received
lenalidomide-based maintenance compared to those in the
nER group (357% vs. 465%; P = 00005). However, 41/115
(357%) of patients who relapsed within 12 months were on
maintenance treatment, suggesting that continuous therapy
does not prevent early disease progression in all.
Depth of response
Responses at the end of induction treatment were deeper in
the nER group, with 725% of the nER group with VGPR or
better compared to 644% in the ER group (Table SIII). A
similar pattern was seen at 100 days post melphalan where
24 participants (138%) in the ER group had progressive dis-
ease (PD) and thus obtained no benefit from the procedure.
Subsequent treatment and survival
Overall, 808% of ER patients and 765% of nER patients
received second-line treatment post progression, 491% of
ER patients and 408% of nER received third-line treatment
and 251% of ER and 196% of nER patients received subse-
quent lines of therapy at the time of analysis. Bortezomib
combinations were the most common second-line treatment
in both groups, given in more than two thirds of cases and
lenalidomide-based regimens the most common third-line
treatment given in approximately half of cases.
Early relapse was associated with short PFS2 (Fig 1A),
with a median of 18 months (95% CI: 16, 20) for the ER
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group as compared to 85 months for the nER group [95%
CI: 83; Not Estimable (NE)]. After first relapse there were
150 PFS2 events in 2376 person-months for the ER group
[incidence rate per 12 person-months (IR per 12 pm): 076;
95% CI: 065, 089] and 386 PFS2 events in 38 516 person-
months for the nER group (IR per 12 pm: 012; 95% CI:
011, 013], risk ratio (RR) 630, 95% CI: 522, 761; score
test P < 0001). Similarly, early relapse was associated with
short OS (Fig 1B), with a median of 26 months (95% CI: 21,
28) for the ER group and 91 months (95% CI: 85, NE) for
the nER group. After first relapse there were 131 deaths in
3 681 person-months for the ER group (IR per 12 pm: 043;
Table I. Clinical characteristics and cytogenetics of patients by relapse group.
Clinical characteristics ER (n = 174) nER (n = 1175) Total (n = 1349) P
Haemoglobin (g/l)
Mean (SD) 1044 (1933) 1119 (2004) 1109 (2009) <00001
Median (range) 1045 (600, 1600) 1110 (330, 1740) 1100 (330, 1740)
Platelets (9 109/l)
Mean (SD) 2265 (9119) 2576 (10162) 2536 (10084) 00001
Median (range) 2225 (340, 6220) 2450 (20, 11120) 2420 (20, 11120)
Plasma cells (%)
Mean (SD) 435 (2661) 346 (2505) 357 (2542) <00001
Median (range) 400 (10, 1420) 290 (00, 1000) 300 (00, 1420)
Missing 12 88 100
b2 microglobulin (mg/l)
Mean (SD) 54 (444) 45 (450) 46 (450) 00002
Median (range) 41 (13, 290) 33 (10, 810) 34 (10, 810)
Missing 15 86 101
Calcium (mmol/l)
Mean (SD) 25 (033) 24 (025) 24 (026) 00382
Median (range) 25 (16, 38) 24 (13, 46) 24 (13, 46)
Missing 0 5 5
ISS
Stage I 39 (224%) 409 (348%) 448 (332%) 00029
Stage II 73 (420%) 442 (376%) 515 (382%)
Stage III 47 (270%) 236 (201%) 283 (210%)
Missing 15 (86%) 88 (75%) 103 (76%)
Cytogenetics ER (n = 78) nER (n = 487) Total (n = 565) P
gain(1q)
Present 39 (500%) 139 (285%) 178 (315%) 00002
Absent 39 (500%) 348 (715%) 387 (685%)
t(4,14)
Present 31 (397%) 51 (105%) 82 (145%) <00001
Absent 47 (603%) 436 (895%) 483 (855%)
t(14,16)
Present 3 (38%) 11 (23%) 14 (25%) 04242
Absent 75 (962%) 476 (977%) 551 (975%)
del(17p)
Present 15 (192%) 30 (62%) 45 (80%) 00001
Absent 63 (808%) 457 (938%) 520 (920%)
t(4,14) and/or del(17p)
Present 42 (538%) 78 (160%) 120 (212%) <00001
Absent 36 (462%) 409 (840%) 445 (788%)
t(14,16) and/or t(14,20)
Present 3 (38%) 14 (29%) 17 (30%) 07174
Absent 75 (962%) 473 (971%) 548 (970%)
Cytogenetic risk
SR 22 (282%) 298 (612%) 320 (566%) <00001
HiR 28 (359%) 146 (300%) 174 (308%)
UHiR 28 (359%) 43 (88%) 71 (126%)
ER, early relapse; nER, non-early relapse; ISS, International Staging System; SR, standard risk; HiR, high risk; UHiR, ultra-high risk.
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95% CI: 036, 051) and 273 deaths in 42 521 person-months
for the nER group (IR per 12pm: 008; 95% CI: 007, 009;
RR 554, 95% CI: 450, 683; score test P < 0001). Almost
three quarters of those in the ER group had died within
three years of trial entry.
Discussion
This is a focussed analysis of outcomes for patients treated
intensively who relapse within 12 months of ASCT in the
Myeloma XI trial and confirms that their prognosis is poor
compared to patients who relapse thereafter. It was not possi-
ble to salvage the majority of early relapsing patients, despite
treatment with multi-novel-agent therapy, suggesting that the
underlying factors for early relapse are predominantly dis-
ease-inherent, not treatment-specific, warranting the search
for novel prognostic tools. This analysis confirms that we are
unable to identify all high-risk patients at diagnosis using cur-
rent staging systems. Certain clinical characteristics were
shown to be more common in patients who relapse early, for
example lower haemoglobin concentration and platelet count
together with heavier bone marrow plasma cell infiltration, in
keeping with higher disease burden and less functional
reserve. However, there was no significant difference in surro-
gate markers of disease burden paraprotein, serum-free light
chain, serum creatinine or lactate dehydrogenase (LDH) level.
We observed that 359% of patients in the early relapse
group had one high-risk lesion and the same number had
Fig 1. (A) Kaplan–Meier curve for progression-free survival 2 landmarked to high-dose melphalan (HDM) administration by relapse group. (B)
Kaplan–Meier curve for overall survival landmarked to HDM administration by relapse group.
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more than one (UHiR) which is more than treble the rate
seen in nER patients. Availability of detailed genetic informa-
tion demonstrates that approximately 70% of early relapse
patients carry a high-risk genetic lesion. Although more
patients in the short PFS group had HiR or UHiR genetics
and ISS 3 disease, early progression was also seen in patients
lacking any of the risk markers analysed and understanding
this phenomenon will be essential for improved prognostic
tools.7 It is the topic of ongoing research to identify addi-
tional predictive markers for early relapse. Whole-body diffu-
sion-weighted magnetic resonance imaging (MRI) or
circulating tumour DNA assessment to extrapolate spatial
heterogeneity that is cryptic to bone marrow biopsy-based
assessment as performed here are emerging as promising
strategies.8,9
In some cases, early relapse in Myeloma XI was seen fol-
lowing deep serological responses to induction therapy,
ASCT and during lenalidomide-based maintenance treat-
ment. This observation challenges the notion of a one-size-
fits-all approach to treatment and future trials will focus on
risk-adapted maintenance therapy such as UK OPTIMUM
MUKnine (ISRCTN16847817). The ability to predict progno-
sis on the basis of diagnostic clinical, laboratory and genetic
factors is a key goal of personalised therapy in myeloma, but
the penetrance of standard genetic abnormalities is heteroge-
neous and likely combines with additional patient, treat-
ment-acquired and tumour-specific factors to generate an
individual’s level of risk.
In conclusion, anaemia, low platelet count, heavy plasma
cell infiltration, advanced ISS stage and high-risk genetic
markers are clinical candidates as prognostic markers for
early relapse in MXI. Early relapse was independent of all
other clinical characteristics and type of induction treatment.
Patients who relapse early are hard to salvage and more likely
to die prematurely from their disease. Further characterisa-
tion and prioritisation of this group of patients for new ther-
apeutic approaches remains an important area of
development with the aim of improving the outlook for
patients with phenotypically high-risk myeloma.
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